Overview

Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Status:
Completed
Trial end date:
2010-12-23
Target enrollment:
Participant gender:
Summary
This was designed as a two part study comprising sequential double-dummy, placebo controlled 3-period randomized crossover studies. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of different doses and dose regimens of MK-8266. Only Part I of the study was completed.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.